Japanese Products Can Find A Home In Emerging Markets With Partners Like Roche
This article was originally published in PharmAsia News
Roche plans to sign China-exclusive in-licensing deals with two Japanese pharma by the end of the year. The head-start of Roche and other western pharma has given them the capability and appetite for larger portfolios in key Asian markets.
You may also be interested in...
CHICAGO - Whether or not the world is flat, licensing deals are no longer simply a transfer of global rights, and pharma companies are trying to determine how best to carve up regional rights and how to coordinate marketing efforts
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.